Investors Who Have Incurred Losses Over $75,000 in Altimmune Encouraged to Contact Securities Litigation Partner at Faruqi & Faruqi, LLP

Faruqi & Faruqi, LLP, a prominent law firm specializing in securities litigation, is actively investigating potential claims on behalf of investors of Altimmune, Inc. ALT. This investigation pertains to potential failing on the part of the company to provide investors with vital information.

Altimmune, Inc. Comes Under Legal Scrutiny

Altimmune, Inc. ALT, a clinical-stage biopharmaceutical company based in Gaithersburg, Maryland, has come to the attention of Faruqi & Faruqi, LLP. The law firm's investigation focuses on whether the company and its executives violated federal securities laws by failing to disclose material information to investors, specifically relating to its intranasal vaccines, immunomodulatory therapies, and treatments for liver disease.

Investment Losses Call to Action

James (Josh) Wilson, a partner at Faruqi & Faruqi, LLP who specializes in securities litigation, urges investors who have experienced losses exceeding $75,000 investing in Altimmune, Inc. ALT stock to get in touch with him directly. The outreach aims to discuss legal options available to these investors. The potential claims would be based on the possible violation of securities laws and the consequent impact on the stock's value, potentially harming investors financially.

The notice serves as a deadline reminder for shareholders who have been significantly affected by their investment in ALT. Faruqi & Faruqi, LLP is committed to ensuring that the rights of investors are upheld and that companies abide by the legal requirements set forth for the conduct of their executives and disclosure of material information to their shareholders.

Altimmune, Investigation, Securities